SCHEMBL3098560

SCHEMBL3098560

COC(=O)CC(=O)OC(C(=O)c1ccc(OC)cc1)c1ccc(OC)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
POLB P06746 2/20 0.58
ALDH1A1 P00352 5/20 0.56
TDP1 Q9NUW8 2/20 0.56
NPSR1 Q6W5P4 1/20 0.54
GAA P10253 1/20 0.47
KLK7 P49862 1/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
SLC2A1 P11166 1/20 0.45
CYP1A2 P05177 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12216991 0.93 MEN1 (0.65) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL6540283 0.89 MAPT (0.53) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL14384221 0.85 MAPT (0.58) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL12217034 0.84 KMT2A (0.51) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL31359577 0.81 MAPT (0.64) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL12240553 0.81 KMT2A (0.68) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL19222625 0.81 MAPT (0.59) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL13204575 0.77 POLB (0.55) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL6207005 0.77 MAPT (0.49) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL6207137 0.77 MAPT (0.49) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 US disclosed
EP-2009006-A1 UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES TORAY INDUSTRIES, INC. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF UROD, UTS2R, SLC14A1 MAPT 414/4885NPC1 1768/4885RAB9A 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.